All In Biotech

Drug Trial Radar · NCT01932242

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

Last checked: Nov 20, 2026Latest source record: May 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

Jul 23, 2013

Primary completion

Apr 19, 2014

Study completion Apr 19, 2014

Sponsor

Lead sponsor
Elusys TherapeuticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.

Conditions

  • Inhalational Anthrax

Interventions

  • ETI-204Biological

    Monoclonal Antibody

  • PlaceboOther

    Placebo for ETI-204

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Adverse EventsTime frame: Up to 191 days or 221 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each arm.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Quintiles

    Overland Park, Kansas

  • DaVita

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.